Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Paradigm Changes in Prostate Cancer Management in Recent Years
10
Mins
August 2025
This article discusses changes in the advanced prostate cancer landscape over the past decade that have induced a paradigm shift in…
Read more
8
Mins
29 Oct 2024
Patient-Centred Therapies for mNSCLC
The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…
5
Mins
29 Oct 2024
Synergy of Tumour and Liquid Biopsy
The symposium took place during the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, with the goal of…
9
Mins
29 Oct 2024
Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond
At the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, the latest advancements in immunotherapy for…
8
Mins
29 Oct 2024
Platinum Resistance in Ovarian Cancer
Approximately 80% of females with ovarian cancer are diagnosed with advanced disease (International Federation of Gynecology and…
5
Mins
29 Oct 2024
From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World
Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…
8
Mins
29 Oct 2024
Novel Approaches to Treat Glioblastoma Multiforme
Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease…
12
Mins
29 Oct 2024
Comparison of Breast Sensibility Following Breast Reconstruction with Two Different Techniques
Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cancer cases per year.1 According to the Spanish…
8
Mins
29 Oct 2024
BRCA
Mutation in Ovarian Cancer: Implications for Screening, Diagnosis, and Preventive Measures
Ovarian cancer is a serious type of cancer that affects women. It has high morbidity and mortality and is the seventh biggest cause of…
7
Mins
29 Oct 2024
10-Year Follow-Up of MammaPrint Prognostic Assay in Early Breast Cancer: A German Registry Study
In modern oncology, the utilisation of gene expression assays has driven the development of personalised treatment strategies for patients…
3
Mins
29 Oct 2024
Congenital Dermatofibrosarcoma Presenting as an Atrophic Plaque
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive sarcoma that most commonly occurs on the trunk of patients…
4
Mins
29 Oct 2024
Effectiveness of Vinorelbine in the Management of Pseudomyogenic Hemangioendothelioma: A Case Report
Pseudomyogenic hemangioendothelioma (PMH) is an uncommon vascular tumour with challenges often in its diagnosis and treatment…
6
Mins
29 Oct 2024
Ependymoma Alongside Hereditary Paraganglioma-Phaeochromocytoma Syndrome Due to a SDHB Mutation: A Case Report
Succinate dehydrogenase (SDH) is a mitochondrial enzyme with a role in both the Krebs cycle and the electron transport chain…
9
Mins
4 Oct 2024
Interview: Sara Tolaney
Sara Tolaney – I started having an interest in medicine from a young age. Part of what drove my interest was having various family members…
5
Mins
17 Sep 2024
Interview: Sarah Blagden
I decided to be an oncologist when I was in medical school, mainly because of the inspiring oncologists I met in training and also my…
12
Mins
12 Sep 2024
Deep Learning for Brain Tumour Analysis
A brain tumour develops as a result of abnormal cell growth in the brain. Tumours are classified as malignant or benign. Malignant tumours…
9
Mins
19 Mar 2024
Updates in
BRAF V600E
-Mutated mCRC
The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer, and is associated with poor prognosis. This…
11
Mins
5 Mar 2024
Follow-Up Care Models Post-Cancer Treatment
After being diagnosed with cancer, patients embark on a journey that involves ongoing treatments, and regular visits to healthcare…
11
Mins
22 Feb 2024
Advancements in Endometrial Cancer Research in 2023
Following the presentation of practice-changing findings from RUBY and NRG-GY018 in patients with advanced or recurrent endometrial cancer at the SGO Annual Meeting in March 2023, data presented and published through the remainder of 2023 show that research in endometrial cancer continues at a pace.
15
Mins
30 Jan 2024
Exploring Advancements and Challenges in Adjuvant Melanoma Treatment
Melanoma of the skin is a common type of cancer that primarily affects younger patients. In Stage III melanoma, which does not involve…
9
Mins
14 Dec 2023
Redefining Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common primary tumour originating from the kidney, and accounts for more than 90% of all renal…
10
Mins
5 Dec 2023
Clinical Perspectives on the Evolution of Non-small Cell Lung Cancer Treatment With Immuno-oncology and
ROS1
Tyrosine Kinase Inhibitors
The non-small cell lung cancer (NSCLC) treatment landscape has rapidly evolved over the last two decades. The addition of immuno-oncology…
10
Mins
5 Dec 2023
Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors for Patients With ER+/HER2- Advanced Breast Cancer
The latest recommendations and upcoming treatment strategies for patients with oestrogen-receptor positive (ER+), human epidermal growth…
3
Mins
5 Dec 2023
Isolated Tumour Cells in Early Endometrial Carcinomas
Endometrial cancer is the most common gynaecologic malignancy in high-income countries due to increased life expectancy. Approximately…
15
Mins
5 Dec 2023
Improving Inclusivity and Diversity in Clinical Trials
Although clinical trials form the backbone of evidence-based medicine, cohorts participating in clinical trials are often poorly…
6
Mins
5 Dec 2023
Dostarlimab and Radiotherapy in A Patient with MSI-H/dMMR Endometrial Cancer
Endometrial carcinoma (EC) is the world’s most common gynaecological malignancy, with a global incidence of 382,069 new cases and 89,929…
12
Mins
1 Dec 2023
Food Insecurity Among Patients with Cancer
This paper explores the overlooked influence of food insecurity on cancer care, its correlation with malnutrition and poor patient…
10
Mins
8 Nov 2023
Disparities in the Incidence and Outcome of Endometrial Cancer: Interviews with Two Key Opinion Leaders
Endometrial cancer is one of the most common gynaecological cancers in high-income countries, and often presents with comorbidities…
6
Mins
8 Nov 2023
Interview: John Marshall
You have to remember that I am a very old oncologist. So, when I first started, there was almost nothing in the world of GI cancer. I was…
11
Mins
27 Oct 2023
The Importance of the Multidisciplinary Team in the Management of Patients with Endometrial Cancer: Interviews with Two Key Opinion Leaders
Endometrial cancer is one of the most common gynaecological cancers in high-income countries, and the incidence is rising significantly…
10
Mins
24 Oct 2023
Recent Developments in Endometrial Cancer Research Presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2023: Interviews with Two Key Opinion Leaders
Endometrial cancer is the most common gynaecological malignancy in developed countries, and often presents at an early stage. Paclitaxel…
8
Mins
12 Oct 2023
Effects of Obesity on Cancer Prognosis and Treatment
Obesity, defined as a BMI greater than or equal to 30 kg/m2, is a condition with rising incidence around the world that contributes…
11
Mins
2 Oct 2023
Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer
As the medical community continues to explore and harness the potential of biosimilars, it is imperative to accumulate robust real-world…
6
Mins
25 Aug 2023
Interview: Karen Canfell
My entry point was through a field that I now still spend a lot of time in, which is cervical cancer control…
7
Mins
7 Aug 2023
PTEN Loss causing Dabrafenib and Trametinib Resistance in Epithelioid Glioblastoma
This case report explores a rare and aggressive variant of glioblastoma that is common in children and young adults…
8
Mins
26 Jul 2023
Interview: Kelly Hirko
My interest in cancer research was sparked during my experience in the Undergraduate Research Opportunity Program (UROP) as an…
10
Mins
16 Mar 2023
The Role of Granulocyte-Colony Stimulating Factor Biosimilars for Supportive Cancer Care: A Year in Review
Chemotherapy-induced neutropenia is a frequent, severe, adverse haematological complication of myelosuppressive and immunosuppressive cytotoxic chemotherapy treatment.
11
Mins
14 Feb 2023
A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022
Ovarian cancer is the seventh most commonly diagnosed cancer among females and the most lethal gynaecologic malignancy globally because of its vague presentation, insidious nature, recurrence, and drug resistance.
6
Mins
6 Feb 2023
Marantic Endocarditis and Lung Adenocarcinoma with Brain Metastasis
This case report aims to unveil the possible differentials and processes involved in the diagnosis of marantic endocarditis…
7
Mins
18 Jan 2023
Radical Radiotherapy in Sinonasal Myopericytoma
The current study reports a case of extended maxillary sinus myopericytoma, diagnosed following the development of an early bulky recurrence 3 months after surgical excision…
9
Mins
8 Dec 2022
EGFR-Mutant Non-small Cell Lung Cancer: Future Perspectives
This review focuses on the state-of-the-art EGFR-TKIs in the treatment of metastatic NSCLC…
11
Mins
5 Dec 2022
Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine
Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.
11
Mins
14 Nov 2022
An Overview of the EORTC-CLTG 2022 Congress
This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes.
14
Mins
4 Nov 2022
The Emerging Role of Homologous Recombination Deficiency Testing and the Progress of PARP Inhibitors in Advanced Ovarian Cancer: Interviews with Three Key Opinion Leaders
Ovarian cancer is the most lethal gynaecologic malignancy worldwide because of its vague presentation, insidious nature, recurrence, and drug resistance.
8
Mins
25 Oct 2022
Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond
This article covers symposia that took place from 9th–13th September, 2022 as part of the European Society for Medical Oncology (ESMO) Congress 2022.
14
Mins
20 Sep 2022
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.
8
Mins
20 Sep 2022
Neratinib as a Potential Therapeutic for Mutant
RAS
and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.
10
Mins
15 Aug 2022
Advancing Patient Care in the Evolving Prostate Cancer Treatment Landscape
Prostate cancer varies at initial diagnosis and in its progression, with non-metastatic and metastatic presentations that may or may not respond to ADT (Figure 1).
6
Mins
11 Aug 2022
The Contradictory Phenomena: Colorectal Cancer in Pregnancy
Colorectal cancer (CRC) ranks as the third most common type of cancer in women. Patients aged 50 years and above constitute the highest percentage of patients diagnosed with the disease.
11
Mins
13 Jul 2022
The Role of Molecular Pathology, Early Testing, and Informatics in the Multidisciplinary Team Approach in Cancer Care: Interviews with Two Key Opinion Leaders
This article discusses how molecular pathology fits alongside traditional anatomical pathology, and the role of molecular MDTs in the management of patients with cancer.
12
Mins
12 Jul 2022
Treatment Landscape and Emerging Therapies in Oesophageal Cancer: Interviews with Two Key Opinion Leaders
EMJ conducted interviews in February 2022 with two key opinion leaders (KOL), Zachary Wilmer Reichenbach, who works in the Department of…
11
Mins
16 Jun 2022
Demystifying the Discussion of Sequencing Panel Size in Oncology Genetic Testing
Clinical laboratories worldwide are implementing next-generation sequencing (NGS) to identify cancer genomic variants and ultimately…
9
Mins
16 Jun 2022
Emetogenicity of Chemotherapy Regimens and Recommended Prophylaxis: A Review of MASCC/ESMO Guidelines
This article reviews the impact of CINV, the emetogenic risk associated with different chemotherapy regimens in solid tumours and haematologic malignancies, and guideline-based recommendations for antiemetic prophylaxis according to emetogenic risk.
12
Mins
9 Jun 2022
Editor's Pick: Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification
Over the last few years, advances in molecular biology and genome sequencing have made it possible to identify the genetic alterations that underlie different health conditions, and these advances are particularly important in the field of oncology. Thanks to these advanced techniques, there has been a change in the way a disease as complex and heterogeneous as breast cancer (BC) is understood.
5
Mins
23 May 2022
Primary Pleural Schwannoma as Incidental Findings: An Unusual Case Report
Schwannomas are neurogenic, benign, slow growing tumours that originate in Schwann’s intersecting fascicles…
13
Mins
12 Apr 2022
Clinical Implications of Emerging Metastatic Breast Cancer Data from ESMO 2021: Interviews with Two Key Opinion Leaders
Around 15–20% of breast cancers are characterised by amplification or overexpression of human epidermal growth factor receptor 2 (HER2)…
4
Mins
7 Apr 2022
Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney
Melanoma is the third most common skin cancer in the UK. Checkpoint inhibitors (CPI) have revolutionised the treatment of melanoma.
10
Mins
22 Mar 2022
Utility of Evidence-Based Clinical Decision Support in Reducing Unwarranted Variations in Diagnosis and Treatment of Breast and Lung Cancer
It is clear that the delivery of advanced healthcare prolongs life. The global average life expectancy has almost doubled since 1900…
5
Mins
22 Mar 2022
Ewing’s Sarcoma of the Lung as a Second Malignancy in Long-Term Survivor of Childhood Hodgkin’s Lymphoma: A Rare Case Report and Literature Review
Long-term survivors of lymphoma frequently suffer relapses, such as Ewing’s sarcoma, following radiotherapy and chemotherapy…
13
Mins
21 Mar 2022
Multidisciplinary Team Approach in Cancer Care: A Review of the Latest Advancements Featured at ESMO 2021
A collaborative approach from healthcare professionals is necessary for the management of patients with cancer to diagnose and treat…
8
Mins
7 Mar 2022
Implementation of MET Molecular Testing in the Clinic: Latest Evidence for Mesenchymal–Epithelial Transition Inhibitors in Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a heterogeneous disease with many genomic mutations. Furthermore, comprehensive genomic…
7
Mins
24 Feb 2022
Evolving the Role for Immunotherapy in Lung Cancer: Extensive-Stage Small Cell Lung Cancer and Unresectable Stage III Non-small Cell Lung Cancer
Lung cancer is classified into NSCLC (85% of patients) and SCLC (15%). NSCLC can be further classified histologically into three main type…
11
Mins
18 Feb 2022
New Developments, Data, and Guideline Updates: Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism Associated with Cancer – Interviews with Key Opinion Leaders
CAT is a serious complication that can affect up to 6% of patients with cancer, and is associated with a 2–5-fold increased risk of…
3
Mins
8 Feb 2022
Interview: Carlos Caldas
Carlos Caldas | Clinician Scientist and Senior Group Leader, Cancer Research UK Cambridge Institute; Chair of Medicine…
14
Mins
3 Feb 2022
Optimising Cholangiocarcinoma Diagnosis and Treatment Focusing on Precision Medicine
This article is based on interviews conducted with Lorenza Rimassa, Arndt Vogel, and Harpreet Wasan. They provided their expert opinion…
10
Mins
21 Jan 2022
Increasing Therapy Options in Solid Tumours: A Consideration of Testing Methodologies in Non-small Cell Lung Cancer and Breast Cancer
Lung cancer has a devastating global impact, claiming almost 2 million lives in 2020.1 Despite advances in treatment, lung cancer remains the world’s leading cause of cancer-related morbidity and mortality.
5
Mins
5 Jan 2022
Thyroid Papillary Carcinoma and Hyperthyroidism: A Case Study
Thyroid cancer is the most common malignant endocrine tumour in the world, but it only accounts for 1% of all cancers…
8
Mins
24 Dec 2021
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
The two most common EGFR mutations differ in their kinase domain structures at different sites, resulting in differential sensitivity to EGFR
6
Mins
9 Dec 2021
Neurofibromatosis Type 1: Burden of Disease in Patients with Plexiform Neurofibromas
NF1 is an autosomal dominant disorder, arising from a mutation in the gene that encodes neurofibromin. It is a tumour-predisposing…
6
Mins
9 Dec 2021
Management and Multi-specialty Approach in the Evolving Treatment Landscape of Neurofibromatosis Type 1 Plexiform Neurofibromas
Neurofibromatosis Type 1 (NF1) is a rare disease, occurring in approximately 1 in 3,000 people. Among the numerous manifestations…
15
Mins
18 Nov 2021
Multidisciplinary Team Approach in Cancer Care: A Review of The Latest Advancements
The management of patients with cancer is complex and requires contribution from a range of healthcare professionals working alongside specialist oncology consultants to address patients’ needs and optimise outcomes.
10
Mins
2 Nov 2021
Navigating the Current Treatment Landscape in Oesophageal Cancer with an Eye Toward the Future
The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…
10
Mins
2 Nov 2021
Editor’s Pick: More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.
11
Mins
2 Nov 2021
Perspectives on Hepatic Metastases and the Minimally Invasive Approach to Resection
The liver is the most common site for colorectal cancer (CRC) metastases, accounting for 80% of patients with Stage IV CRC and 40% as the only site of distant disease. Of the patients with CRC, 20–25% present with synchronous metastases and 50–60% will develop metachronous disease. Liver metastases develop in the absence of lymph node involvement and, presumably, this occurs via the haematogenous route (the portal circulation) in gastrointestinal tumours from where tumour cells can embolise via the mesenteric veins.
7
Mins
2 Nov 2021
Evaluation of Treatment Outcome and Acute Toxicity in Patients Undergoing Adjuvant Therapy in Ductal Carcinoma Pancreas: A Prospective Observational Study
Pancreatic cancer is the eleventh most commonly diagnosed cancer worldwide and is the seventh leading cause of cancer-related death. It can arise from both exocrine (95%) and endocrine portion (5%) of the pancreatic gland. The most common histology is ductal adenocarcinoma of the pancreas, which accounts for around 80% of all pancreatic cancers, while 65% of the cases arise in the pancreatic head, 15% in the body or tail, and 20% involve the gland diffusely.
10
Mins
2 Nov 2021
Emerging Role of Aurora A in Radioresistance: A Comprehensive Review
Radioresistance is known to create complications in the treatment of cancer.1 Radiation-induced altered adaptive responses by tumour cells or tissues are considered to be primary reasons behind the failure of radiotherapy.2 Acquirement of radioresistance followed by treatment failure and locoregional recurrence is a multifaceted process. Emerging data have suggested various molecular biomarkers necessitate radioresistance in cancer.
10
Mins
2 Nov 2021
Management of Lower Limb Soft Tissue Sarcomas with Major Neurovascular Involvement: Current and Future Perspectives
Soft tissue sarcomas (STS) are a group of rare mesenchymal tumours that can arise in patients of any age and in a variety of anatomic sites. It is estimated that STS make up 1% of all adult malignancies and that their incidence is on the rise. The lower limb is the most commonly affected site, with approximately 28% of STS arising there. With at least 50 different histologic subtypes, STS are considered highly heterogenous in terms of their histopathology and their tendency to metastasise. Undifferentiated pleomorphic sarcomas and liposarcomas are the most common histopathologic subtypes in adult patients.
16
Mins
21 Oct 2021
The Emerging Role and Value of Homologous Recombination Deficiency Testing in Advanced Ovarian Cancer: Interviews with Four Key Opinion Leaders
Ovarian cancer is the seventh most common cancer in females,1-3 and the most lethal gynaecologic malignancy globally because of its vague…
11
Mins
18 Oct 2021
Moving Towards Precision Medicine for Patients with Cholangiocarcinoma
Current diagnostic approaches in CCA are inadequate, without additional histological confirmation and, with no efficient screening…
12
Mins
23 Aug 2021
Balancing Risk of Thromboembolism and Bleeding in Patients with Cancer: Selecting Anticoagulant Therapy Based on Recent Clinical Trials
Venous thromboembolism (VTE) is one of the main reasons for morbidity and mortality among patients with malignancies. In addition, in this…
10
Mins
13 Aug 2021
Trial Outcomes and Sub-Analyses of Direct Oral Anticoagulants in the Treatment of Cancer-Related Venous Thromboembolism: Interviews with Key Opinion Leaders
EMJ conducted interviews with two key opinion leaders and specialists in the prevention and treatment of cancer-related venous…
10
Mins
29 Jun 2021
PARP Inhibitors in Advanced Ovarian Cancer: A Review of Long-term Efficacy and Survival Rates
This article discusses the results published in 2020 and early 2021 from key clinical trials of PARP inhibitors in patients with advanced ovarian cancer in terms of long-term efficacy and survival rates.
10
Mins
4 May 2021
Reimagining Treatment of HR+, HER2- Early Breast Cancer
Dr Prat explained that there are three main variables that should be considered when determining the risk of recurrence for…
11
Mins
23 Mar 2021
Addressing the Unmet Need in Treatment of Nonmelanoma Skin Cancers: Interviews with Two Key Opinion Leaders
Nonmelanoma skin cancers (NMSC) are a diverse group of cutaneous malignancies and are the most common forms of human neoplasia worldwide…
3
Mins
19 Feb 2021
Final Results from the ClarIDHy Phase III Study of Ivosidenib Versus Placebo in Patients with Previously Treated Cholangiocarcinoma and an Isocitrate Dehydrogenase 1 (IDH1) Mutation
Cholangiocarcinoma (CCA) is a rare cancer for which there are limited effective therapies.1,2 Mutations in the isocitrate dehydrogenase 1 gene (IDH1)…
5
Mins
8 Feb 2021
Streptococcus suis and an Incidentally Diagnosed Metastatic Colon Cancer
Streptococcus suis is a zoonotic gram-positive bacterium that is usually acquired through direct contact with swine or pork…
10
Mins
12 Jan 2021
Expanding Possibilities in EGFR-Mutated Advanced NSCLC: Interviews with Four Key Opinion Leaders
Worldwide, there were approximately 2.10 million patients diagnosed with, and 1.77 million deaths caused by, lung cancer in 2018. Approximately…
6
Mins
16 Dec 2020
3rd Breast Cancer Virtual Masterclass Symposium: MONARCH 2, a Phase III Study of Abemaciclib or Placebo in Combination with Fulvestrant
More than 70% of patients diagnosed with metastatic breast cancer present with oestrogen-HR+ disease and are therefore candidates for endocrine…
8
Mins
5 Nov 2020
Next-Generation Sequencing Standard of Care for Molecular Profiling
Given that COVID-19 has posed unique challenges in cancer care, a number of speakers addressed, with evidence, the impact of COVID-19…
11
Mins
5 Nov 2020
Oncogenic Drivers in Advanced NSCLC: Navigating an Evolving Landscape to Optimise Patient Outcomes
The oncology community has been experiencing an unprecedented moment in lung cancer diagnosis and treatment; however, despite significant…
6
Mins
5 Nov 2020
Interview: Dr Vinay Prasad
You have an impressive background in science communication within the medical field, not only working with patients as a haematologist…
11
Mins
5 Nov 2020
The Importance of Molecular Testing in the Treatment of Cholangiocarcinoma
Cholangiocarcinomas (CCA) belong to the constellation of biliary tract cancers (BTC), along with gallbladder carcinomas and ampullary carcinomas…
8
Mins
5 Nov 2020
race against time
Breast cancer (BC), which is the most prevalent malignancy in women worldwide, is a heterogeneous disease, in which human epidermal growth…
9
Mins
5 Nov 2020
Association of Tumour Location and Recurrence in Patients with Non-Muscle Invasive Bladder Cancer
Risk stratification and prognosis estimation is important in patients with non-muscle invasive bladder cancer (NMIBC). NMIBC has a high probability…
8
Mins
5 Nov 2020
Phosphate and Oxysterols May Mediate an Inverse Relationship Between Atherosclerosis and Cancer
“If it’s not one thing, it’s another” is the sardonic title of an article by Li et al.1 which describes a puzzling inverse relationship between cancer…
7
Mins
5 Nov 2020
Nasopharyngeal Rhabdomyosarcoma: A Rare Malignancy Incidentally Found in a Middle-Aged Male with a Diagnostic Dilemma
Rhabdomyosarcoma (RMS) is an infrequent and aggressive malignancy that emerges from embryonic mesenchymal cells…
10
Mins
21 Sep 2020
Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update
Urothelial cancer is the 9th most common cancer in the world and the 10th most common cancer in the UK…
7
Mins
17 Sep 2020
Editor's Pick: Tumour-Associated Hypoxia: Can We Give Chimeric Antigen Receptor T Cells More Breathing Space?
Chimeric antigen receptors (CAR) are fusion molecules that couple the binding of a native tumour-associated target to the delivery of a bespoke T…
9
Mins
17 Sep 2020
Metastasis: A Bane of Breast Cancer Therapy
Breast cancer is one of the most commonly diagnosed cancers among women.1 Despite advances in treatment for breast cancer…
12
Mins
17 Sep 2020
Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy
Cancer is a genetic and epigenetic disease of multicellularity, driving transformed cells to uncontrolled growth, invasion, and metastasis. In cancer, intracellular mechanisms controlling cellular proliferation are damaged first, which allows certain cells to progress to malignant transformation…
14
Mins
10 Sep 2020
Unmet Medical Need in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutations: A Review
Colorectal cancer (CRC) is the most common gastrointestinal malignancy. Worldwide, it is the second most common cancer in females…
8
Mins
26 Aug 2020
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer
MONARCH 2 was a global, randomised, double-blind, Phase III study of abemaciclib or placebo in combination with fulvestrant in premenopausal…
14
Mins
26 Aug 2020
Latest Developments in Advanced Breast Cancer Treatment: A Discussion with Two Key Opinion Leaders about the CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib
The introduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of advanced breast cancer (ABC; inoperable locally advanced…
10
Mins
24 Aug 2020
Adaptations and Advancement of Biologic Immunotherapy in the Management of Immunologically Cold Solid Malignancies
Contemporary breakthroughs within cancer immunotherapy are frequently cited amongst the most promising of therapeutic directions for medical oncology…
10
Mins
4 Aug 2020
Initiatives to Improve Control, Resource Use, and Quality of Life Associated with Chemotherapy-Induced Nausea and Vomiting
This review set out to identify the initiatives needed to achieve better cancer-induced nausea and vomiting (CINV) control worldwide…
9
Mins
23 Jun 2020
Breast Cancer Immunotherapy: From Biology to Current Clinical Applications
The complexity behind the treatment of breast cancer arises, in part, from the presence of biologically distinct subtypes…
4
Mins
18 May 2020
The COVID-19 Conundrum and Cancer – Making Perfect Sense of Imperfect Data
March 11th 2020 marked the day that the World Health Organization (WHO) escalated the coronavirus SARS-CoV-2 (COVID-19) outbreak from a public health…
12
Mins
24 Feb 2020
From Traditional Histology to Next-Generation Pathology: A Review of The Workflow for the Characterisation and Molecular Profiling of Non-Small Cell Lung Cancer Samples
In accordance with ‘taking care’ of the cancer patient, the management of non-small cell lung cancer (NSCLC) is currently carried…
12
Mins
8 Jan 2020
Editor's Pick: Precision Medicine in Lung Cancer
Lung cancer has a devastating global impact. Claiming over 2 million lives in 2018, it is the world’s leading cause of cancer-related morbidity…
8
Mins
20 Dec 2019
BCG-Unresponsive Bladder Cancer: New Frontiers in the Treatment Landscape
This meeting took place on 28th September 2019, as part of the Ferring-organised Meet-The-Expert symposium at the European Society of Medical Oncology. Main topic is discussion of new treatment modalities in the management of high-risk, non-muscle invasive bladder cancer.
10
Mins
12 Dec 2019
Boosting Cancer Immunotherapies with Optical Biosensor Nanotechnologies
Cancer immunotherapy has been profiled as one of the major breakthroughs of the decade and will probably remain a paramount biomedical landmark in…
9
Mins
12 Nov 2019
Inflection Point: Novel Treatment Options are Forcing Next-Generation Sequencing into Standard of Care for Molecular Profiling in Oncology
With a sustained number of new drugs or combination drugs entering standard of care this year, molecular testing should be…
9
Mins
12 Nov 2019
The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer
Despite the impressive advances that have been made in cancer diagnosis and therapy, there still exist groups of patients who are not responding to standard anticancer treatments…
3
Mins
12 Nov 2019
Epithelial Myoepithelial Carcinoma of the Hard Palate: A Case Report with a Review of the Literature
Epithelial myoepithelial carcinoma (EMC) was initially described by Donath et al…
8
Mins
12 Nov 2019
PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
Physiologically, cells are equipped with DNA damage repair systems that can correct various errors…
3
Mins
12 Nov 2019
Branchial Cleft Cyst – A Misdiagnosed Developmental Anomaly
The branchial cleft’s embryological journey begins between the first 3–8 weeks of intrauterine life. Five mesodermal arches form by the inpouching…
9
Mins
12 Nov 2019
Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS
The drug neratinib (HKI-272, Nerlynx®) was originally developed by Wyeth Research Laboratories, with its initial characterisation published in 2004…
11
Mins
12 Nov 2019
Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer
In the era of target and immunotherapy, the multidisciplinary approach of lung cancer is now mandatory. Close collaboration between pulmonologists…
7
Mins
12 Nov 2019
Follow-Up of Accessory Breast Cancer Patient: Case Report
Accessory breast is a congenital atavism condition. Accessory breast tissue may arise anywhere along the mammary line because of the failure of complete…
6
Mins
13 Jun 2019
A New Twist to Ibuprofen: Alternative Action in Alternative Splicing
Ibuprofen belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) used to treat diverse inflammatory processes, pain, or fever…
11
Mins
13 Jun 2019
The Heart of the Matter: A Unique Convergence of Cardiac Neoplasm, Hereditary Nonpolyposis Colorectal Cancer, and Spindle Cell Sarcoma
Cardiac tumours are rare, with their incidence estimated between 0.0017–0.2800%,1 and the vast majority are metastatic lesions…
9
Mins
13 Jun 2019
Obesity and the Effects of Weight Reduction: A Spotlight on Women with Hormone Receptor-Positive Breast Cancer and Heart Disease
There is a connection between increased body mass, or adipose tissue, and higher risk of developing cancer, particularly in hormone-stimulated neoplastic…
11
Mins
20 May 2019
A Review of Gene Expression Profiling in Early-Stage ER+/HER2- Breast Cancer With A Focus on The PAM50 Risk of Recurrence Assay
Over 70% of patients with early-stage breast cancer are diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative…
13
Mins
14 Mar 2019
MET Inhibition in Non-Small Cell Lung Cancer
There has been a decrease in the number of incidences of lung cancer recorded among men over the past few decades as well as among women…
2
Mins
11 Feb 2019
World Cancer Day Message: Cancer Awareness and Empowerment – Every citizen should act as an ambassador!
Whoever you are, you have the power to reduce the impact of cancer for yourself, the people you love, and for the world. It’s time to make a personal…
16
Mins
13 Dec 2018
iBiopsy® for Precision Medicine
A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to…
9
Mins
6 Dec 2018
The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy
Adding a molecular perspective to the traditional multidisciplinary management of cancer patients is substantially hampering the adoption of precision…
8
Mins
6 Dec 2018
Prediction with Precision: Does TAILORx Make Chemotherapy a Personalised Treatment?
Adjuvant chemotherapy (CT) is commonly recommended to breast cancer patients following surgery. However, not all patients benefit from it, and the…
10
Mins
6 Dec 2018
Genomic Profiling Clinical Trials in Cancer of Unknown Primary
Cancer of unknown primary (CUP) accounts for 3–5% of all cancers, and prognosis is poor for most patients, with a median survival of 6–9 months…
13
Mins
6 Dec 2018
Editor's Pick: Novel Targets and Therapies in T Cell Lymphoma
This review presents the recent advances in our understanding of the cellular pathogenesis of T cell non-Hodgkin lymphoma (NHL) and the potential of…
12
Mins
6 Dec 2018
Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are a rare group of heterogeneous malignancies with >50 histologic subtypes that have varying biological behaviour and…
8
Mins
6 Dec 2018
Clinical Issues for Prostate-Specific Antigen Screening: A Narrative Review
Prostate cancer, with its remarkably high prevalence, frequently creates clinical problems in terms of screening and diagnosis, as well as identifying…
11
Mins
6 Dec 2018
Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
The prognosis of mantle cell lymphoma (MCL) has improved rapidly over recent years with the evolution of new management strategies. The disease, once…
14
Mins
3 Dec 2018
Realising the Full Potential of Biosimilars: Interviews with Three Key Opinion Leaders
These valuable insights were obtained from a series of interviews conducted between 19th September and 8th October 2018 by the European Medical Journal…
14
Mins
4 Oct 2018
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
Dr Birrer presented on the current landscape of platinum-sensitive recurrent ovarian cancer (PSR OC), including USA and European treatment guidelines.
3
Mins
4 Sep 2018
Rare Cancer Continues to Take Lives
The number of lives lost due to cancer each year is astronomical. According to the World Health Organization (WHO): “Cancer is the second leading cause…
9
Mins
7 Jun 2018
Initiatives to Improve Safety of Oral Anticancer Agents Delivered by Community Pharmacists
With the recent growth in oral anticancer agents (OAA), pharmacists working in the community have recognised the urgent need to develop safe and…
9
Mins
7 Jun 2018
Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy
Lung cancer is the most frequently diagnosed cancer type and the leading cause of cancer-related deaths worldwide. According to the last GLOBOCAN…
4
Mins
8 Jan 2018
Delivering Healthcare to Modern Conflict Zones
The nature of recent conflicts around the world has brought about new challenges for the provision of healthcare.
5
Mins
19 Dec 2017
How to Help Empower Cancer Patients
One of the themes that ran through the recent ‘War on Cancer’ event, organised by The Economist, conducted on 21st November, was problems in…
8
Mins
30 Nov 2017
Sustaining Cancer Care Through Collaborative Stewardship
Cancer care has undergone rapid changes in recent years, providing dramatically improved outcomes for many patients.
10
Mins
30 Nov 2017
Editor’s Pick: Screening for Pancreatic Cancer: Current Status and Future Directions
Pancreatic ductal adenocarcinoma is a lethal disease for a multitude of reasons, including difficulty of early detection, early metastatic spread, and…
9
Mins
30 Nov 2017
Role of Genetic Variations in Determining Treatment Outcome in Head and Neck Cancer
Worldwide, head and neck squamous cell carcinoma (HNSCC) is responsible for >550,000 diagnoses and 380,000 deaths annually. It originates in the upper…
9
Mins
24 Nov 2017
Editor’s Pick: Simple, Low-Cost, and Timely Optical Biosensors for the Detection of Epigenetic Biomarkers: The Future of Cancer Diagnosis
The cancer burden continues to grow with enormous physical, emotional, and financial pressure on individuals, families, communities, and health systems.
9
Mins
24 Oct 2017
The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer
Pancreatic cancer (PC) still represents an unresolved therapeutic challenge due to the associated poor prognosis and the lack of responsiveness to…
9
Mins
24 Oct 2017
Post-Surgical Strategies for Prostate Cancer: Clinicopathologic and Genomics Criteria
Radical prostatectomy is widely used as the primary modality of treatment for clinically localised prostate cancer.
9
Mins
24 Oct 2017
Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management
FDG-PET is widely used for cancer staging before treatment and detection of recurrence during post-treatment surveillance.
10
Mins
24 Oct 2017
Understanding the Microenvironment of Melanoma Cells for the Development of Target Drug Delivery Systems
Melanoma is the most aggressive and deadly form of skin cancer. The high rate of patient death is related to advanced melanoma metastasis, which usually…
10
Mins
24 Oct 2017
Chemotherapy for Extracranial Germ Cell Tumours in Paediatric, Adolescent, and Young Adult Patients
Extracranial germ cell tumours are derived from dysregulated, unipotent to totipotent, primordial germ cells and can arise from heterogeneous sites and…
9
Mins
24 Oct 2017
Malignant Pleural Mesothelioma: Spotlight on Recent Advances in Diagnosis and Treatment
Pleural malignancies constitute either primary pleural malignancies, such as malignant pleural mesothelioma (MPM), or secondary pleural tumours, either…
3
Mins
12 Oct 2017
How to Play an Important Role in Raising Awareness for Mesothelioma in Health Education Week
Blue is the colour of hope that brings a broader awareness to a rare cancer called mesothelioma.
7
Mins
31 Aug 2017
Editor’s Pick: Renal Involvement in Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disorder that represents almost 10% of haematologic malignancies.
8
Mins
31 Aug 2017
A Theoretical View of Ovarian Cancer Relapse
Ovarian cancer (OC) is a disease that almost invariably relapses even after optimal primary cytoreductive surgery and standard first-line platinum-based…
Loading posts...
« Previous
1
…
18
19
20
21
22
…
29
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View